US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

8.40

-0.5400-6.04%

Post-market: 8.500.1000+1.19%19:16 EDT

Volume:1.39M

Turnover:12.03M

Market Cap:262.84M

PE:-2.95

High:9.25

Open:8.90

Low:8.40

Close:8.94

52wk High:50.40

52wk Low:8.40

Shares:31.29M

Float Shares:15.69M

Volume Ratio:0.67

T/O Rate:8.88%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.8500

EPS(LYR):-2.8503

ROE:-33.63%

ROA:-21.86%

PB:0.92

PE(LYR):-2.95

Loading ...

Overview Company News Filings

Allergy Therapeutics Deepens Real-World Data on Grassmuno® With New GRASS Study

Spyre Therapeutics Completes First-in-Human Study of SPY001-001, De-risking Early Pipeline

Knight Therapeutics price target raised to C$8.50 from C$8 at RBC Capital

Investor Outlook: Knight Therapeutics beats estimates on product growth

Oppenheimer Adjusts Pelthos Therapeutics Price Target to $62 From $60, Maintains Outperform Rating

MT Newswires Live

Aquestive Therapeutics Announces Key Legal Leadership Transition

LENZ Therapeutics Inc expected to post a loss of 97 cents a share - Earnings Preview

Stoke Therapeutics price target raised to $60 from $36 at Canaccord

Novartis to Acquire Synnovation Therapeutics Breast Cancer Drug Assets for Up to $3 Billion

Press Release: Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer

PYC Therapeutics: Strengthened Balance Sheet and Expanded Development Plan Underpin Continued Buy Rating

Novartis to acquire Pikavation Therapeutics from Synnovation Therapeutics

Regulatory Timing Risks Mount for Ovid Therapeutics as FDA Funding and Staffing Volatility Threaten Drug Approval Timelines

Damora Therapeutics: Buy Rating on Differentiated CALR Pipeline, Clear Regulatory Path, and Solid Cash Runway

Press Release: Damora Therapeutics Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call

Press Release: Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update

Plus Therapeutics Is Maintained at Buy by D. Boral Capital

Larimar Therapeutics: Undervalued First-in-Class Frataxin Replacement with Favorable Regulatory Path and 2026 Inflection Point

Pelthos Therapeutics Price Target Maintained With a $60.00/Share by HC Wainwright & Co.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/LENZ/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LENZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":8.4,"timestamp":1774641600000,"preClose":8.94,"halted":0,"volume":1393631,"hourTrading":{"tag":"盘后","latestPrice":8.5,"preClose":8.4,"latestTime":"19:16 EDT","volume":25181,"amount":211529.72,"timestamp":1774653413550,"change":0.1,"changeRate":0.011905,"amplitude":0.011905},"delay":0,"changeRate":-0.060402684563758295,"floatShares":15692500,"shares":31289969,"eps":-2.85,"marketStatus":"Market Closed","change":-0.54,"latestTime":"03-27 16:00:00 EDT","open":8.9,"high":9.25,"low":8.395,"amount":12026989.540177,"amplitude":0.095638,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.85,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":8.94,"preHourTrading":{"tag":"盘前","latestPrice":8.95,"preClose":8.94,"latestTime":"09:25 EDT","volume":2891,"amount":25925.149467,"timestamp":1774617913255,"change":0.01,"changeRate":0.001119,"amplitude":0.016779},"postHourTrading":{"tag":"盘后","latestPrice":8.5,"preClose":8.4,"latestTime":"19:16 EDT","volume":25181,"amount":211529.72,"timestamp":1774653413550,"change":0.1,"changeRate":0.011905,"amplitude":0.011905},"volumeRatio":0.670644,"impliedVol":1.3191,"impliedVolPercentile":0.9877},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","floatShares":15692500,"roa":"-21.86%","roe":"-33.63%","lyrEps":-2.850329,"volumeRatio":0.670644,"shares":31289969,"dividePrice":0,"high":9.25,"amplitude":0.095638,"preClose":8.94,"low":8.395,"week52Low":8.395,"pbRate":"0.92","psRate":"13.77","week52High":50.4,"institutionHeld":0,"latestPrice":8.4,"eps":-2.85,"divideRate":0,"volume":1393631,"delay":0,"ttmEps":-2.85,"open":8.9,"prevYearClose":16,"prevWeekClose":10.48,"prevMonthClose":13.49,"prevQuarterClose":16,"fiveDayClose":10.48,"twentyDayClose":13.49,"sixtyDayClose":16.12},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LENZ\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-24","symbol":"LENZ","fiscalQuarterEnding":"2025/12","expectedEps":-0.91,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1774324800000,"reportTimeType":"pre","actualEps":-1.16},{"market":"US","date":"2026-01-07","symbol":"LENZ","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1767762000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-11-05","symbol":"LENZ","fiscalQuarterEnding":"2025/09","expectedEps":-0.67,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762318800000,"reportTimeType":"pre","actualEps":-0.59},{"market":"US","date":"2025-07-30","symbol":"LENZ","fiscalQuarterEnding":"2025/06","expectedEps":-0.58,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1753848000000,"reportTimeType":"pre","actualEps":-0.53},{"market":"US","date":"2024-05-08","symbol":"LENZ","fiscalQuarterEnding":"2024/03","expectedEps":-0.84,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715140800000,"reportTimeType":"pre","actualEps":-3.53}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LENZ\",market:\"US\",,,undefined,":[{"executeDate":"2024-03-22","recordDate":"2024-03-18","paymentDate":"2024-03-21","value":1.03,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LENZ\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5714,"buy":0.4286,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5714,"analysts":7,"updateTime":1742270400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LENZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LENZ","date":"2026-03-27","current":-2.947368,"percent":1,"low":-26.69966,"twenty":-16.980184,"median":-11.233899,"eighty":-7.489126,"high":-3.413108,"avg":-12.467749,"sd":5.207963,"marketCap":280308282},"quantilePoints":[{"date":"2024-03-28","current":-7.959158,"twenty":-7.219077,"median":-6.108955,"eighty":-6.016992,"marketCap":556886354},{"date":"2024-04-05","current":-7.492045,"twenty":-7.873034,"median":-7.667213,"eighty":-6.662191,"marketCap":524203432},{"date":"2024-04-12","current":-7.929963,"twenty":-7.855517,"median":-7.667213,"eighty":-7.432197,"marketCap":554843672},{"date":"2024-04-19","current":-6.382653,"twenty":-7.855517,"median":-7.488396,"eighty":-6.783348,"marketCap":446581492},{"date":"2024-04-26","current":-5.638193,"twenty":-7.716113,"median":-7.451903,"eighty":-5.889996,"marketCap":394493084},{"date":"2024-05-03","current":-5.988527,"twenty":-7.671592,"median":-6.864363,"eighty":-5.803142,"marketCap":419005276},{"date":"2024-05-10","current":-5.317808,"twenty":-7.667213,"median":-6.108955,"eighty":-5.803142,"marketCap":393230653},{"date":"2024-05-17","current":-5.708011,"twenty":-7.597146,"median":-6.0013,"eighty":-5.749862,"marketCap":422084590},{"date":"2024-05-24","current":-5.428308,"twenty":-7.489126,"median":-6.006774,"eighty":-5.719496,"marketCap":401401679},{"date":"2024-05-31","current":-5.355793,"twenty":-7.479638,"median":-5.988527,"eighty":-5.522773,"marketCap":396039443},{"date":"2024-06-07","current":-5.193496,"twenty":-7.457742,"median":-5.904593,"eighty":-5.428999,"marketCap":384038248},{"date":"2024-06-14","current":-6.433167,"twenty":-7.451903,"median":-5.930138,"eighty":-5.428308,"marketCap":475706952},{"date":"2024-06-21","current":-6.236339,"twenty":-7.425628,"median":-5.992177,"eighty":-5.43107,"marketCap":461152311},{"date":"2024-06-28","current":-6.150011,"twenty":-7.389135,"median":-6.0013,"eighty":-5.439358,"marketCap":454768696},{"date":"2024-07-05","current":-6.098214,"twenty":-7.269437,"median":-6.014073,"eighty":-5.469746,"marketCap":450938528},{"date":"2024-07-12","current":-6.771573,"twenty":-6.771573,"median":-6.098214,"eighty":-5.493918,"marketCap":500730721},{"date":"2024-07-15","current":-7.261916,"twenty":-7.163847,"median":-6.103393,"eighty":-5.509112,"marketCap":536989651},{"date":"2024-08-02","current":-8.498134,"twenty":-7.266429,"median":-6.108573,"eighty":-5.524305,"marketCap":628403011},{"date":"2024-08-09","current":-8.328931,"twenty":-7.474529,"median":-6.146558,"eighty":-5.597209,"marketCap":615891126},{"date":"2024-08-16","current":-8.944708,"twenty":-7.671592,"median":-6.236339,"eighty":-5.641258,"marketCap":621424629},{"date":"2024-08-23","current":-8.79431,"twenty":-7.94748,"median":-6.352018,"eighty":-5.670717,"marketCap":610975896},{"date":"2024-08-30","current":-8.746816,"twenty":-8.006409,"median":-6.382653,"eighty":-5.719496,"marketCap":607676296},{"date":"2024-09-06","current":-9.451311,"twenty":-8.199004,"median":-6.419354,"eighty":-5.743293,"marketCap":656620360},{"date":"2024-09-13","current":-8.17293,"twenty":-8.352945,"median":-6.434893,"eighty":-5.773217,"marketCap":567806132},{"date":"2024-09-20","current":-8.7389,"twenty":-8.507104,"median":-6.459289,"eighty":-5.788545,"marketCap":607126363},{"date":"2024-09-27","current":-8.806184,"twenty":-8.638371,"median":-6.616182,"eighty":-5.792924,"marketCap":611800796},{"date":"2024-10-04","current":-8.897214,"twenty":-8.745233,"median":-7.269437,"eighty":-5.800953,"marketCap":618125029},{"date":"2024-10-11","current":-9.340491,"twenty":-8.850511,"median":-7.455552,"eighty":-5.81701,"marketCap":648921294},{"date":"2024-10-18","current":-10.417023,"twenty":-8.905129,"median":-7.492045,"eighty":-5.857882,"marketCap":723712222},{"date":"2024-10-25","current":-9.902504,"twenty":-9.0017,"median":-7.670862,"eighty":-5.904593,"marketCap":687966558},{"date":"2024-10-31","current":-10.939457,"twenty":-9.257377,"median":-7.718702,"eighty":-5.904593,"marketCap":760007820},{"date":"2024-11-08","current":-14.709443,"twenty":-9.419648,"median":-7.959158,"eighty":-5.955683,"marketCap":894466512},{"date":"2024-11-15","current":-15.344855,"twenty":-9.514636,"median":-8.00261,"eighty":-5.970448,"marketCap":933105265},{"date":"2024-11-22","current":-15.521232,"twenty":-9.76398,"median":-8.132103,"eighty":-5.988527,"marketCap":943830613},{"date":"2024-11-29","current":-16.100113,"twenty":-9.924668,"median":-8.17293,"eighty":-5.994366,"marketCap":979031755},{"date":"2024-12-06","current":-16.33076,"twenty":-10.388526,"median":-8.285117,"eighty":-6.004584,"marketCap":993057210},{"date":"2024-12-13","current":-13.920266,"twenty":-10.815972,"median":-8.351032,"eighty":-6.018452,"marketCap":846477455},{"date":"2024-12-20","current":-13.694141,"twenty":-11.182468,"median":-8.50374,"eighty":-6.082845,"marketCap":832727009},{"date":"2024-12-27","current":-14.476534,"twenty":-12.093039,"median":-8.531114,"eighty":-6.098214,"marketCap":880303552},{"date":"2025-01-03","current":-12.794163,"twenty":-13.449021,"median":-8.618187,"eighty":-6.102358,"marketCap":778000234},{"date":"2025-01-10","current":-11.912274,"twenty":-13.190334,"median":-8.707238,"eighty":-6.108649,"marketCap":724373495},{"date":"2025-01-17","current":-10.130408,"twenty":-13.019383,"median":-8.746816,"eighty":-6.115785,"marketCap":616019980},{"date":"2025-01-24","current":-11.197719,"twenty":-12.871045,"median":-8.79431,"eighty":-6.143105,"marketCap":680922085},{"date":"2025-01-31","current":-11.523339,"twenty":-12.794163,"median":-8.877425,"eighty":-6.150011,"marketCap":700722728},{"date":"2025-02-07","current":-12.070562,"twenty":-12.328345,"median":-8.905129,"eighty":-6.232886,"marketCap":733998807},{"date":"2025-02-14","current":-11.432889,"twenty":-12.292165,"median":-8.964497,"eighty":-6.236339,"marketCap":695222549},{"date":"2025-02-21","current":-11.279124,"twenty":-12.151063,"median":-8.998138,"eighty":-6.308164,"marketCap":685872246},{"date":"2025-02-28","current":-9.62841,"twenty":-12.079607,"median":-9.059485,"eighty":-6.342695,"marketCap":585493990},{"date":"2025-03-07","current":-10.297741,"twenty":-11.943932,"median":-9.320702,"eighty":-6.355126,"marketCap":626195310},{"date":"2025-03-14","current":-11.193196,"twenty":-11.879712,"median":-9.419648,"eighty":-6.365485,"marketCap":680647077},{"date":"2025-03-21","current":-14.554795,"twenty":-11.943932,"median":-9.482973,"eighty":-6.379634,"marketCap":724377586},{"date":"2025-03-28","current":-14.68208,"twenty":-12.421509,"median":-9.574004,"eighty":-6.398202,"marketCap":730712447},{"date":"2025-04-04","current":-12.728528,"twenty":-13.089934,"median":-9.668992,"eighty":-6.415901,"marketCap":633486102},{"date":"2025-04-11","current":-10.2603,"twenty":-12.90813,"median":-9.741473,"eighty":-6.42488,"marketCap":510644883},{"date":"2025-04-17","current":-12.761733,"twenty":-12.945214,"median":-9.779811,"eighty":-6.430405,"marketCap":635138674},{"date":"2025-04-25","current":-15.833323,"twenty":-13.271407,"median":-9.84549,"eighty":-6.435239,"marketCap":788008663},{"date":"2025-05-02","current":-15.982746,"twenty":-13.932929,"median":-9.940463,"eighty":-6.440764,"marketCap":795445305},{"date":"2025-05-09","current":-15.25222,"twenty":-14.136351,"median":-10.102399,"eighty":-6.452984,"marketCap":728141003},{"date":"2025-05-16","current":-16.118891,"twenty":-14.245886,"median":-10.138549,"eighty":-6.460191,"marketCap":769515850},{"date":"2025-05-23","current":-16.637714,"twenty":-14.356129,"median":-10.19625,"eighty":-6.460792,"marketCap":794284465},{"date":"2025-05-30","current":-17.410053,"twenty":-14.523491,"median":-10.236057,"eighty":-6.585104,"marketCap":831155927},{"date":"2025-06-06","current":-17.864023,"twenty":-14.65894,"median":-10.342966,"eighty":-6.96771,"marketCap":852828466},{"date":"2025-06-13","current":-17.439532,"twenty":-14.747436,"median":-10.384797,"eighty":-7.264924,"marketCap":832563235},{"date":"2025-06-20","current":-17.704839,"twenty":-14.88454,"median":-10.454615,"eighty":-7.299361,"marketCap":845229004},{"date":"2025-06-27","current":-17.752005,"twenty":-15.005667,"median":-10.623361,"eighty":-7.425628,"marketCap":847480696},{"date":"2025-07-03","current":-19.178768,"twenty":-15.33581,"median":-10.694071,"eighty":-7.451903,"marketCap":915594389},{"date":"2025-07-11","current":-20.198727,"twenty":-15.529319,"median":-10.766979,"eighty":-7.459202,"marketCap":964287236},{"date":"2025-07-18","current":-20.381494,"twenty":-15.833323,"median":-10.791578,"eighty":-7.484747,"marketCap":973012543},{"date":"2025-07-25","current":-19.691695,"twenty":-16.100113,"median":-11.044571,"eighty":-7.492045,"marketCap":940081543},{"date":"2025-08-01","current":-16.20487,"twenty":-16.158905,"median":-11.077981,"eighty":-7.667213,"marketCap":849102797},{"date":"2025-08-08","current":-17.484059,"twenty":-16.20487,"median":-11.141188,"eighty":-7.667213,"marketCap":916129723},{"date":"2025-08-15","current":-22.268769,"twenty":-16.33076,"median":-11.193196,"eighty":-7.674511,"marketCap":1166838947},{"date":"2025-08-22","current":-21.691773,"twenty":-16.434778,"median":-11.220775,"eighty":-7.693556,"marketCap":1136605525},{"date":"2025-08-29","current":-20.793619,"twenty":-16.611183,"median":-11.233899,"eighty":-7.743848,"marketCap":1089544067},{"date":"2025-09-05","current":-21.729877,"twenty":-16.749673,"median":-11.252126,"eighty":-7.89274,"marketCap":1138602072},{"date":"2025-09-12","current":-22.214335,"twenty":-16.928962,"median":-11.290275,"eighty":-7.953319,"marketCap":1163986737},{"date":"2025-09-19","current":-22.693351,"twenty":-17.073997,"median":-11.339198,"eighty":-7.982513,"marketCap":1189086182},{"date":"2025-09-26","current":-21.789753,"twenty":-17.210778,"median":-11.419321,"eighty":-7.998378,"marketCap":1141739502},{"date":"2025-10-03","current":-26.302295,"twenty":-17.347559,"median":-11.473592,"eighty":-8.003646,"marketCap":1378187678},{"date":"2025-10-10","current":-25.175521,"twenty":-17.497557,"median":-11.534645,"eighty":-8.0071,"marketCap":1319146940},{"date":"2025-10-17","current":-22.018374,"twenty":-17.690689,"median":-11.749464,"eighty":-8.107241,"marketCap":1153718783},{"date":"2025-10-24","current":-16.034033,"twenty":-17.707197,"median":-11.991418,"eighty":-8.145558,"marketCap":840151237},{"date":"2025-10-31","current":-15.563946,"twenty":-17.690689,"median":-12.292165,"eighty":-8.168128,"marketCap":815519652},{"date":"2025-11-07","current":-10.439663,"twenty":-17.665927,"median":-12.292165,"eighty":-8.196087,"marketCap":614718687},{"date":"2025-11-14","current":-14.07658,"twenty":-17.595178,"median":-12.325665,"eighty":-8.25011,"marketCap":828871278},{"date":"2025-11-21","current":-14.730193,"twenty":-17.553908,"median":-12.761733,"eighty":-8.286974,"marketCap":867357940},{"date":"2025-11-28","current":-16.218091,"twenty":-17.524554,"median":-12.861347,"eighty":-8.308212,"marketCap":954969853},{"date":"2025-12-05","current":-14.825843,"twenty":-17.466248,"median":-13.119398,"eighty":-8.337771,"marketCap":872990135},{"date":"2025-12-12","current":-13.01911,"twenty":-17.42774,"median":-13.221067,"eighty":-8.354198,"marketCap":766604240},{"date":"2025-12-19","current":-9.070865,"twenty":-17.407695,"median":-13.037789,"eighty":-8.414622,"marketCap":534119770},{"date":"2025-12-26","current":-9.108063,"twenty":-17.390007,"median":-12.866196,"eighty":-8.500376,"marketCap":536310068},{"date":"2026-01-02","current":-8.502276,"twenty":-17.333409,"median":-12.777948,"eighty":-8.502276,"marketCap":500639504},{"date":"2026-01-09","current":-8.098418,"twenty":-17.315721,"median":-12.328345,"eighty":-8.502276,"marketCap":476859127},{"date":"2026-01-16","current":-9.639455,"twenty":-17.280347,"median":-12.249123,"eighty":-8.498134,"marketCap":567600037},{"date":"2026-01-23","current":-11.302713,"twenty":-17.228465,"median":-12.093174,"eighty":-8.501448,"marketCap":665537640},{"date":"2026-01-30","current":-9.448154,"twenty":-17.210778,"median":-11.871572,"eighty":-8.502276,"marketCap":556335648},{"date":"2026-02-06","current":-7.42355,"twenty":-17.195449,"median":-11.633633,"eighty":-8.39709,"marketCap":437120866},{"date":"2026-02-13","current":-6.892157,"twenty":-17.156729,"median":-11.509772,"eighty":-8.290687,"marketCap":405830897},{"date":"2026-02-20","current":-6.403276,"twenty":-17.117721,"median":-11.432889,"eighty":-8.236123,"marketCap":377044126},{"date":"2026-02-27","current":-7.184423,"twenty":-17.08343,"median":-11.396709,"eighty":-8.118629,"marketCap":423040380},{"date":"2026-03-06","current":-6.40859,"twenty":-17.073997,"median":-11.306259,"eighty":-7.995871,"marketCap":377357026},{"date":"2026-03-13","current":-6.281056,"twenty":-17.036729,"median":-11.290275,"eighty":-7.848663,"marketCap":369847433},{"date":"2026-03-20","current":-6.105697,"twenty":-16.999628,"median":-11.252126,"eighty":-7.671592,"marketCap":359521743},{"date":"2026-03-27","current":-3.413108,"twenty":-16.980184,"median":-11.233899,"eighty":-7.489126,"marketCap":280308282}],"updateTime":1774706646997},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LENZ\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2621796758","title":"Allergy Therapeutics Deepens Real-World Data on Grassmuno® With New GRASS Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2621796758","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621796758?lang=en_us&edition=fundamental","pubTime":"2026-03-21 00:32","pubTimestamp":1774024341,"startTime":"0","endTime":"0","summary":"Allergy Therapeutics ($GB:AGY) announced an update on their ongoing clinical study. The GRASS (Grass MATA MPL Real-world Assessment Study) is a pro...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/allergy-therapeutics-deepens-real-world-data-on-grassmuno-with-new-grass-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/allergy-therapeutics-deepens-real-world-data-on-grassmuno-with-new-grass-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LENZ","BK4139","BK4539"],"gpt_icon":0},{"id":"2621758706","title":"Spyre Therapeutics Completes First-in-Human Study of SPY001-001, De-risking Early Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2621758706","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621758706?lang=en_us&edition=fundamental","pubTime":"2026-03-21 00:30","pubTimestamp":1774024236,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics, Inc ($SYRE) announced an update on their ongoing clinical study. Spyre Therapeutics, Inc. (SYRE) has completed a Phase 1 trial ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/spyre-therapeutics-completes-first-in-human-study-of-spy001-001-de-risking-early-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/spyre-therapeutics-completes-first-in-human-study-of-spy001-001-de-risking-early-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","SYRE","BK4539","BK4007","BK4139"],"gpt_icon":0},{"id":"2621588907","title":"Knight Therapeutics price target raised to C$8.50 from C$8 at RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2621588907","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621588907?lang=en_us&edition=fundamental","pubTime":"2026-03-20 23:50","pubTimestamp":1774021834,"startTime":"0","endTime":"0","summary":"RBC Capital raised the firm’s price target on Knight Therapeutics (KHTRF) to C$8.50 from C$8 and keeps an Outperform rating on the shares. Publishe...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/knight-therapeutics-price-target-raised-to-c8-50-from-c8-at-rbc-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/knight-therapeutics-price-target-raised-to-c8-50-from-c8-at-rbc-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2621935755","title":"Investor Outlook: Knight Therapeutics beats estimates on product growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2621935755","media":"Bloomberg","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621935755?lang=en_us&edition=fundamental","pubTime":"2026-03-20 23:28","pubTimestamp":1774020480,"startTime":"0","endTime":"0","summary":"Knight Therapeutics beats expectations as CEO highlights product launches and cautious outlook tied to early-stage growth across key markets.","market":"sg","thumbnail":"https://www.bnnbloomberg.ca/resizer/v2/TAHQIFI2HRIIEFJT47KXPFIA74.jpg?smart=true&auth=adadeb8787fbd5b7357f87efef303fa4c3782416a98c9c6cbc9f9fea2bbbf2b6&width=500&height=333","type":0,"news_type":0,"thumbnails":["https://www.bnnbloomberg.ca/resizer/v2/TAHQIFI2HRIIEFJT47KXPFIA74.jpg?smart=true&auth=adadeb8787fbd5b7357f87efef303fa4c3782416a98c9c6cbc9f9fea2bbbf2b6&width=500&height=333"],"rights":{"source":"bnn_bloomberg_highlight","url":"https://www.bnnbloomberg.ca/investing/investor-outlook/2026/03/20/investor-outlook-knight-therapeutics-beats-estimates-on-product-growth/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bnnbloomberg.ca/investing/investor-outlook/2026/03/20/investor-outlook-knight-therapeutics-beats-estimates-on-product-growth/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"bnn_bloomberg_highlight","symbols":["BK4139","LENZ","BK4007","BK4539"],"gpt_icon":0},{"id":"2620113731","title":"Oppenheimer Adjusts Pelthos Therapeutics Price Target to $62 From $60, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2620113731","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620113731?lang=en_us&edition=fundamental","pubTime":"2026-03-20 21:42","pubTimestamp":1774014159,"startTime":"0","endTime":"0","summary":"Pelthos Therapeutics Inc. (PTHS) has an average rating of Buy and mean price target of $58.33, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","OPY"],"gpt_icon":0},{"id":"2620733954","title":"Aquestive Therapeutics Announces Key Legal Leadership Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2620733954","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620733954?lang=en_us&edition=fundamental","pubTime":"2026-03-20 19:57","pubTimestamp":1774007871,"startTime":"0","endTime":"0","summary":"Aquestive Therapeutics ( ($AQST) ) just unveiled an announcement. On March 16, 2026, Aquestive Therapeutics agreed that longtime Chief Legal Office...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aquestive-therapeutics-announces-key-legal-leadership-transition?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aquestive-therapeutics-announces-key-legal-leadership-transition?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","LENZ","BK4007"],"gpt_icon":0},{"id":"2620800527","title":"LENZ Therapeutics Inc  expected to post a loss of 97 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2620800527","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620800527?lang=en_us&edition=fundamental","pubTime":"2026-03-20 19:18","pubTimestamp":1774005486,"startTime":"0","endTime":"0","summary":"LENZ Therapeutics Inc  expected to post a loss of97cents a share - Earnings Preview LENZ Therapeutics Inc LENZ.OQ LENZ.O is expected to  show a rise in quarterly revenue when it reports  results on Ma","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nL8N4080W9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","LENZ","BK4007"],"gpt_icon":0},{"id":"2620380738","title":"Stoke Therapeutics price target raised to $60 from $36 at Canaccord","url":"https://stock-news.laohu8.com/highlight/detail?id=2620380738","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620380738?lang=en_us&edition=fundamental","pubTime":"2026-03-20 19:17","pubTimestamp":1774005449,"startTime":"0","endTime":"0","summary":"Canaccord raised the firm’s price target on Stoke Therapeutics (STOK) to $60 from $36 and keeps a Buy rating on the shares. The firm believes conse...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/stoke-therapeutics-price-target-raised-to-60-from-36-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/stoke-therapeutics-price-target-raised-to-60-from-36-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"1121796113","title":"Novartis to Acquire Synnovation Therapeutics Breast Cancer Drug Assets for Up to $3 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1121796113","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121796113?lang=en_us&edition=fundamental","pubTime":"2026-03-20 19:02","pubTimestamp":1774004550,"startTime":"0","endTime":"0","summary":"Novartis AG has agreed to acquire an experimental breast cancer drug from Synnovation Therapeutics for up to $3 billion, aiming to strengthen its oncology product pipeline. According to a statement...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJT1NW94.SGD","LU0211331839.USD","BK4585","IE0009355771.USD","BK4588","IE00BJJMRZ35.SGD","LU0070302665.USD","IE00B2B36J28.USD","BK4139","LU0208291251.USD","LENZ","IE0002141913.USD","NVS","BK4578","BK4532","IE00B4R5TH58.HKD","LU0320765489.SGD","BK4007","IE00BFTCPJ56.SGD","BK4539"],"gpt_icon":0},{"id":"2620780623","title":"Press Release: Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2620780623","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620780623?lang=en_us&edition=fundamental","pubTime":"2026-03-20 19:00","pubTimestamp":1774004400,"startTime":"0","endTime":"0","summary":"-- Thomas A. Zalewski, a Partner at Day Pitney LLP, appointed Chief Legal. Officer and Chief Compliance Officer effective April 2, 2026. -- Lori J. Braender to remain in a non-executive role as Corporate Secretary. after nearly eight years as Chief Legal Officer, Chief Compliance Officer. Mr. Zalewski joins Aquestive as Chief Legal Officer and Chief Compliance Officer effective April 2, 2026. Mr. Zalewski is a Partner at Day Pitney LLP, where he serves as Chair of the firm's Healthcare and Life Sciences practice. He has considerable experience advising life sciences, technology, and healthcare companies on a broad range of strategic and commercial matters, including mergers and acquisitions, licensing and intellectual property transactions, corporate governance, and regulatory matters. Mr. Zalewski has also served as outside general counsel to emerging and middle-market companie","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDMO","AQST","BK4099","03160","BK4139","R","TM","BK4022","BK4585","LENZ","BK4232","BK4007","BK4555","BK4604","BK4588","BK4539"],"gpt_icon":0},{"id":"2620780397","title":"PYC Therapeutics: Strengthened Balance Sheet and Expanded Development Plan Underpin Continued Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2620780397","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620780397?lang=en_us&edition=fundamental","pubTime":"2026-03-20 18:55","pubTimestamp":1774004116,"startTime":"0","endTime":"0","summary":"David Martin PhD, an analyst from Bloom Burton, maintained the Buy rating on PYC Therapeutics Limited. The associated price target was raised to A$...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/pyc-therapeutics-strengthened-balance-sheet-and-expanded-development-plan-underpin-continued-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/pyc-therapeutics-strengthened-balance-sheet-and-expanded-development-plan-underpin-continued-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2620827127","title":"Novartis to acquire Pikavation Therapeutics from Synnovation Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2620827127","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620827127?lang=en_us&edition=fundamental","pubTime":"2026-03-20 18:15","pubTimestamp":1774001741,"startTime":"0","endTime":"0","summary":"Novartis (NVS) announced that it has entered into an agreement with Synnovation Therapeutics to acquire SNV4818, a pan-mutant-selective PI3Kalpha i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novartis-to-acquire-pikavation-therapeutics-from-synnovation-therapeutics-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novartis-to-acquire-pikavation-therapeutics-from-synnovation-therapeutics-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BFTCPJ56.SGD","BK4007","IE00B4R5TH58.HKD","IE00B2B36J28.USD","BK4532","BK4539","IE0009355771.USD","LU0070302665.USD","BK4578","LENZ","IE0002141913.USD","LU0320765489.SGD","BK4585","LU0208291251.USD","LU0211331839.USD","IE00BJT1NW94.SGD","NVS","BK4588","BK4139","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2620207715","title":"Regulatory Timing Risks Mount for Ovid Therapeutics as FDA Funding and Staffing Volatility Threaten Drug Approval Timelines","url":"https://stock-news.laohu8.com/highlight/detail?id=2620207715","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620207715?lang=en_us&edition=fundamental","pubTime":"2026-03-20 14:00","pubTimestamp":1773986436,"startTime":"0","endTime":"0","summary":"Ovid Therapeutics (OVID) has disclosed a new risk, in the Taxation & Government Incentives category. Ovid Therapeutics faces heightened regulatory ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/regulatory-timing-risks-mount-for-ovid-therapeutics-as-fda-funding-and-staffing-volatility-threaten-drug-approval-timelines?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/regulatory-timing-risks-mount-for-ovid-therapeutics-as-fda-funding-and-staffing-volatility-threaten-drug-approval-timelines?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4007","BK4139","BK4585","OVID","LENZ","BK4588","LABU"],"gpt_icon":0},{"id":"2620024002","title":"Damora Therapeutics: Buy Rating on Differentiated CALR Pipeline, Clear Regulatory Path, and Solid Cash Runway","url":"https://stock-news.laohu8.com/highlight/detail?id=2620024002","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620024002?lang=en_us&edition=fundamental","pubTime":"2026-03-20 13:35","pubTimestamp":1773984919,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Damora Therapeutics yesterday and set a price target of $45.00. Sam Slutsky has give...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/damora-therapeutics-buy-rating-on-differentiated-calr-pipeline-clear-regulatory-path-and-solid-cash-runway-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/damora-therapeutics-buy-rating-on-differentiated-calr-pipeline-clear-regulatory-path-and-solid-cash-runway-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2620276758","title":"Press Release: Damora Therapeutics Reports Full-Year 2025 Financial Results and Recent Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2620276758","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620276758?lang=en_us&edition=fundamental","pubTime":"2026-03-20 04:10","pubTimestamp":1773951000,"startTime":"0","endTime":"0","summary":"-- DMR-001 on track for IND or CTA submission in mid-2026, with two clinical proof-of-concept datasets expected beginning mid-2027 --. -- Strong financial position with approximately $535 million in cash and cash equivalents as of February 28, 2026, expected to fund operations into Phase 3 development of DMR-001 --. BOSTON, March 19, 2026  -- Damora Therapeutics, Inc.   , a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced its operating and financial results for the year ended December 31, 2025, and recent corporate highlights.\"At Damora Therapeutics, we strive to rapidly bring forward best-in-class medicines to dramatically improve the lives of patients with blood disorders. Today, we are well on the path to achieving our goal based on recent progress, including the acquisition of three highly innovative mutant calreticulin  targeted therapies and two oversubscribed financings extending our cash runway into Phase 3 developm","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BHPRN162.USD","BK4007","CMC","BK4106","LU2746668461.USD","LU1363072403.SGD","BK4226","LU2237443895.HKD","BK4581","BK4144","BK4561","IE00B1BXHZ80.USD","LU0971096721.USD","LU0267386448.USD","LU2237443978.SGD","LU2746668974.SGD","BK4585","BK4139","IE00BZ1G4Q59.USD","LENZ","LU2237443382.USD","BK4006","IE00BFXG1179.USD","BK4588","BK4590","IE00BKVL7J92.USD","LU2237443465.HKD","LU2237443622.USD","DMRA","LU0170899867.USD","ET","LU0149725797.USD","LU0882574139.USD","BK4539","XELA","LU2237443549.SGD"],"gpt_icon":0},{"id":"2620279076","title":"Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2620279076","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620279076?lang=en_us&edition=fundamental","pubTime":"2026-03-20 04:03","pubTimestamp":1773950580,"startTime":"0","endTime":"0","summary":"RICHMOND, Calif., March  19, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company today announced that the company has scheduled the release of its fourth qua","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/19/3259419/33816/en/Sangamo-Therapeutics-Announces-Fourth-Quarter-and-Full-Year-2025-Earnings-Call.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"gpt_icon":0},{"id":"2620766332","title":"Press Release: Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2620766332","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620766332?lang=en_us&edition=fundamental","pubTime":"2026-03-20 04:01","pubTimestamp":1773950460,"startTime":"0","endTime":"0","summary":"-- Positive 12-month Phase 2 data for NDV-01 in non-muscle invasive bladder. cancer  demonstrated a 95% complete response  rate at any time. and a durable 76% CR rate at 12 months, with favorable safety profile. through 2029, including completion of the NDV-01 RESCUE program. \"NDV-01's compelling efficacy, durability, and favorable safety profile, combined with operational ease-of-use are the cornerstone of its differentiated product profile and best-in-class potential,\" said Raj S. Pruthi, MD, Chief Medical Officer-Oncology of Relmada Therapeutics. \"We continue to be encouraged by the high response rates and durable clinical benefit observed through 12 months, including in the BCG-unresponsive population, alongside a favorable safety profile with no >= Grade 3 treatment-related adverse events and no treatment-related discontinuations. Our clinical program builds on the urologic oncology community's comfort with conventional Gem/Doce's efficacy and safety profile with a sustained relea","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861220207.SGD","CR","LU0106831901.USD","LU1668664300.SGD","RLMD","BK4161","LU1791807156.HKD","LU2360107671.USD","LU1861217088.USD","BK4166","BK4139","DFS","BK4585","LENZ","BK4007","BK4588","BK4539"],"gpt_icon":0},{"id":"2620727347","title":"Plus Therapeutics Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2620727347","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620727347?lang=en_us&edition=fundamental","pubTime":"2026-03-20 02:48","pubTimestamp":1773946080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PSTV/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 19, 2026 14:48 ET (18:48 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"gpt_icon":0},{"id":"2620278970","title":"Larimar Therapeutics: Undervalued First-in-Class Frataxin Replacement with Favorable Regulatory Path and 2026 Inflection Point","url":"https://stock-news.laohu8.com/highlight/detail?id=2620278970","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620278970?lang=en_us&edition=fundamental","pubTime":"2026-03-20 01:35","pubTimestamp":1773941715,"startTime":"0","endTime":"0","summary":"William Blair analyst Myles Minter has reiterated their bullish stance on LRMR stock, giving a Buy rating on March 3. Myles Minter has given his Bu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/larimar-therapeutics-undervalued-first-in-class-frataxin-replacement-with-favorable-regulatory-path-and-2026-inflection-point-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/larimar-therapeutics-undervalued-first-in-class-frataxin-replacement-with-favorable-regulatory-path-and-2026-inflection-point-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4539","LENZ","BK4139"],"gpt_icon":0},{"id":"2620220308","title":"Pelthos Therapeutics Price Target Maintained With a $60.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2620220308","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620220308?lang=en_us&edition=fundamental","pubTime":"2026-03-20 01:13","pubTimestamp":1773940380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PTHS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 19, 2026 13:13 ET (17:13 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"gpt_icon":0}],"pageSize":20,"totalPage":13,"pageCount":8,"totalSize":260,"code":"91000000","status":"200"}]}}